drugset / Trial / NCT04771013
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
Phase 2
Completed
22 enrolled
Catholic University of Honduras
Pontificia Universidad Catolica de Chile · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.
Timeline
- Start
- 2021-02-10
- Primary completion
- 2021-05-14
- Completion
- 2021-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymic peptides | Peptide | 250 mg | Oral |